Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (106 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-07-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientctpriortherapynew
  Phrases that lowered it: multiplekgbodysingle18 and
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 31.3% (raises risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Phase: 1/2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 98.2% (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Maximum age: 85 (lowers risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Blinding: double (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain NCT03585270 · started 2019 · scored riskier than 96% of active trials completed
• Clazosentan in Aneurysmal Subarachnoid Hemorrhage NCT00940095 · started 2009 · scored riskier than 97% of active trials terminated
• Ketamine Infusion in Neurologic Deficit NCT02636218 · started 2016 · scored riskier than 67% of active trials completed
• Evaluating Neuroprotection in Aneurysm Coiling Therapy NCT00728182 · started 2008 · scored riskier than 97% of active trials completed
• China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis NCT01763320 · started 2014 · scored riskier than 52% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.